展望Therapeutics宣布按市场定价500万美元注册直接发行

2026-04-22 20:48

Outlook Therapeutics (OTLK) on Wednesday said it has entered into an agreement for the purchase and sale of an aggregate of 16.12M shares of its common stock at an offering price of $0.31 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.
OTLK -12.74% premarket to $0.2787.
Additionally, in a concurrent private placement, the company will issue unregistered warrants to purchase up to an aggregate of 16.12M shares of common stock at an exercise price of $0.31 per share.
The closing of the offering is expected to occur on or about April 23, 2026.
The aggregate gross proceeds to the company from the offering are expected to be approximately $5 million.
Source: Press Release

More on Outlook Therapeutics